<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>From the French ANSM drug interactions document of September 2016, p. 28</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>ATAZANAVIR</b></p>

<p><b>RxNorm: 343047 </b></p>

<p><b>ATC: J05AE08</b></p></td>
<td valign="top"><p>Risk of decrease of the plasma concentrations of the atazanavir</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>CYANOCOBALAMIN</b></p>

<p><b>RxNorm: 11248</b></p>

<p><b>ATC: </b></p>

<p><b>B03BA01 B03BA02 B03BA51</b></p></td>
<td valign="top"><p>Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>METABOLIZED TYROSINE-KINASE INHIBITORS </b></p>

<p><b>CLASS CODE: </b></p>

<p><b>L01XE</b></p></td>
<td valign="top"><p>Risk of decrease of the bioavailabilty of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption</p></td>
<td valign="top"><p><b>Take into account</b></p>

<p><b>-</b>except with the vandetanib</p></td>
</tr>

<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>ITRACONAZOLE</b></p>

<p><b>RxNorm: 28031 </b></p>

<p><b>ATC: J02AC02</b></p></td>
<td valign="top"><p>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>KETOCONAZOLE</b></p>

<p><b>RxNorm: 6135 </b></p>

<p><b>ATC: </b></p>

<p><b>D01AC08 G01AF11 J02AB02</b></p></td>
<td valign="top"><p>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p>

<p><b></b></p></td>
<td valign="top"><p>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p><b>-</b>only with the oral suspension form of posaconazole</p></td>
</tr>

<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>RILPIVIRINE</b></p>

<p><b>RxNorm: 1102270</b></p>

<p><b>ATC: J05AG05</b></p></td>
<td valign="top"><p>Risk of decrease of the plasma concentrations of the rilpivirine</p></td>
<td valign="top"><p><b>Take into account</b></p>

<p>If necessary, use an active H2 antihistmine in one dose per day, to be taken at least 12 hours before, or at least 4 hours after. </p></td>
</tr>

<tr>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: A02BA-001</b></p></td>
<td valign="top"><p><b>ULIPRISTAL</b></p>

<p><b>RxNorm: 1005921</b></p>

<p><b>ATC: G03AD02</b></p></td>
<td valign="top"><p>Risk of decrease of the effect of the ulipristal due to decrease of its absorption </p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

</tbody>
</table>

